![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
(MM) | NASDAQ:IDIX | NASDAQ | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 24.50 | 0.00 | 01:00:00 |
Delaware | 000-49839 | 45-0478605 | ||
(State or other jurisdiction
of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
60 Hampshire Street
Cambridge, MA |
02139 |
|
(Address of principal executive offices) | (Zip Code) |
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| consented to the General Waiver and Consent by Novartis; |
| agreed to the Stockholders Agreement Amendment; and |
| agreed to an increase of up to $10.0 million in shares of Common Stock issuable under the Companys existing registration statement on Form S-3 (File No. 33-153471) as declared effective by the Securities and Exchange Commission on October 17, 2008. |
(d) | The following exhibits are included in this report: |
Exhibit No. | Description | |||
10.1 |
Amendment No. 6 to the Development, License and
Commercialization Agreement dated April 6, 2011, among the
Registrant, Idenix (Cayman) Limited and Novartis Pharma AG
|
|||
|
||||
10.2 |
Amendment No. 1 dated April 6, 2011 to the Amended and
Restated Stockholders Agreement, dated July 27, 2004, by and
among the Registrant, Novartis Pharma AG and the stockholders
identified on the signature pages thereto
|
|||
|
||||
10.3 |
Second Amendment to the Letter Agreement dated April 6, 2011,
by and between the Registrant and Novartis Pharma AG
|
IDENIX PHARMACEUTICALS, INC. | ||||||
|
||||||
Date: April 7, 2011
|
By: | /s/ Maria Stahl | ||||
|
|
|||||
|
Senior Vice President and General Counsel |
Exhibit No. | Description | |||
10.1 |
Amendment No. 6 to the Development, License and
Commercialization Agreement dated April 6, 2011, among the
Registrant, Idenix (Cayman) Limited and Novartis Pharma AG
|
|||
|
||||
10.2 |
Amendment No. 1 dated April 6, 2011 to the Amended and
Restated Stockholders Agreement, dated July 27, 2004, by and
among the Registrant, Novartis Pharma AG and the stockholders
identified on the signature pages thereto
|
|||
|
||||
10.3 |
Second Amendment to the Letter Agreement dated April 6, 2011,
by and between the Registrant and Novartis Pharma AG
|
1 Year (MM) Chart |
1 Month (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions